Ariad Pharmaceuticals (ARIA) 9.23 $ARIA
Ariad Pharmaceuticals Has Returned 29.6% Since SmarTrend Recommendation (ARIA)
Comtex SmarTrend(R) - Wed Apr 22, 11:23AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 4 months, Ariad Pharmaceuticals has returned 29.63% as of today's recent price of $9.23.
ARIA: 9.23 (-0.04)
ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
Business Wire - Wed Apr 22, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the issuance of its first U.S. patent on brigatinib, ARIAD's investigational ALK inhibitor. The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, "Phosphorous Derivatives as Kinase Inhibitors." The patent provides composition-of-matter protection through at least December 30, 2030 for ARIAD's investigational ALK inhibitor, brigatinib. Additional patent applications covering brigatinib are pending in the U.S. and in other countries.
ARIA: 9.23 (-0.04)
ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting
Business Wire - Tue Apr 21, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at the American Association for Cancer Research (AACR) Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC), who are resistant to crizotinib.
ARIA: 9.23 (-0.04)
ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
Business Wire - Fri Apr 17, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The new results include an analysis of safety and efficacy for patients treated at select doses of brigatinib and an evaluation of intracranial central nervous system (CNS) antitumor activity.
ARIA: 9.23 (-0.04)
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech
at The Street - Fri Apr 17, 4:59AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 136.49 (+1.22), XBIT: 27.55 (+0.18), ARIA: 9.23 (-0.04)
24.2% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Wed Apr 15, 9:51AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 4 months, Ariad Pharmaceuticals has returned 24.16% as of today's recent price of $8.84.
ARIA: 9.23 (-0.04)
Ariad Pharmaceuticals Shares Up 17.1% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Wed Apr 08, 9:27AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 4 months, Ariad Pharmaceuticals has returned 17.13% as of today's recent price of $8.34.
ARIA: 9.23 (-0.04)
Pre-market Equity Watch on Biotech -- ARIAD Pharma, Array BioPharma, Neurocrine Biosciences, Coronado Biosciences, and Ironwood Pharma
PR Newswire - Tue Apr 07, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
NBIX: 43.23 (-0.43), IRWD: 15.07 (-0.19), CNDO: 4.09 (-0.09), ARIA: 9.23 (-0.04), ARRY: 7.25 (-0.10)
Critical Alerts For Advanced Micro Devices, Illumina, Coca-Cola, Ariad Pharmaceuticals and Ambarella Released By InvestorsObserver
PR Newswire - Mon Apr 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, ILMN, KO, ARIA and AMBA.
AMBA: 74.57 (+0.18), KO: 41.31 (+0.53), AMD: 2.28 (-0.07), ILMN: 190.04 (-9.27), ARIA: 9.23 (-0.04)
Iclusig cleared in Canada
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 8:01AM CDT
ARIA: 9.23 (-0.04)
ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada
Business Wire - Mon Apr 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that Health Canada has approved the use of Iclusig(TM) (as ponatinib hydrochloride) in Canada for the treatment of adult patients with all phases of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ ALL that is T315I mutation positive, or where there is prior TKI resistance or intolerance.
ARIA: 9.23 (-0.04)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 19.1% (ARIA)
Comtex SmarTrend(R) - Tue Mar 31, 9:58AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 3 months, Ariad Pharmaceuticals has returned 19.10% as of today's recent price of $8.48.
ARIA: 9.23 (-0.04)
Big Selloff on Wall Street as Stocks Plummet on Fed Jitters
at The Street - Wed Mar 25, 3:27PM CDT
Wednesday was a kick-you-in-the-guts kind of day.
MU: 29.50 (+0.95), XOM: 87.46 (+0.58), IBB: 363.84 (-0.66), KRFT: 88.25 (-0.22), SOXX: 96.88 (+1.35), KFX: 11.02 (-0.01), NVDA: 22.31 (+0.25), RDS.A: 62.36 (-0.06), AMD: 2.28 (-0.07), ALXN: 188.19 (+1.41), NLNK: 53.12 (-0.07), BP: 43.24 (+0.46), ARIA: 9.23 (-0.04), CVX: 109.50 (-0.23), XLE: 81.89 (+0.54), LXK: 44.24 (+1.17)
Stocks Sell Off on Fed Jitters; Oil Rallies as Yemen Fights Intensify
at The Street - Wed Mar 25, 2:22PM CDT
Stocks are lower in a volatile trading session on Wednesday.
MU: 29.50 (+0.95), IBB: 363.84 (-0.66), KRFT: 88.25 (-0.22), SOXX: 96.88 (+1.35), KFX: 11.02 (-0.01), NVDA: 22.31 (+0.25), AMD: 2.28 (-0.07), ALXN: 188.19 (+1.41), NLNK: 53.12 (-0.07), ARIA: 9.23 (-0.04), BRK.A: 214,789.00 (+1,349.00), LXK: 44.24 (+1.17)
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court
Business Wire - Wed Mar 25, 8:28AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig(R) (ponatinib) on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy.
ARIA: 9.23 (-0.04)
ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel
Business Wire - Tue Mar 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig(R) (ponatinib) in Israel for adult patients with:
ARIA: 9.23 (-0.04)
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 4.42% Rise
Comtex SmarTrend(R) - Thu Mar 19, 4:37PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.57 to a high of $9.09. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $8.78 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 9.23 (-0.04)
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting
Business Wire - Thu Mar 19, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place Saturday, April 18 through Wednesday, April 22, 2015, in Philadelphia.
ARIA: 9.23 (-0.04)
Ariad Pharmaceuticals Has Returned 29.6% Since SmarTrend Recommendation (ARIA)
Comtex SmarTrend(R) - Wed Apr 22, 11:23AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 4 months, Ariad Pharmaceuticals has returned 29.63% as of today's recent price of $9.23.
ARIA: 9.23 (-0.04)
ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
Business Wire - Wed Apr 22, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the issuance of its first U.S. patent on brigatinib, ARIAD's investigational ALK inhibitor. The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, "Phosphorous Derivatives as Kinase Inhibitors." The patent provides composition-of-matter protection through at least December 30, 2030 for ARIAD's investigational ALK inhibitor, brigatinib. Additional patent applications covering brigatinib are pending in the U.S. and in other countries.
ARIA: 9.23 (-0.04)
ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting
Business Wire - Tue Apr 21, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at the American Association for Cancer Research (AACR) Annual Meeting 2015. Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC), who are resistant to crizotinib.
ARIA: 9.23 (-0.04)
ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
Business Wire - Fri Apr 17, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The new results include an analysis of safety and efficacy for patients treated at select doses of brigatinib and an evaluation of intracranial central nervous system (CNS) antitumor activity.
ARIA: 9.23 (-0.04)
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech
at The Street - Fri Apr 17, 4:59AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 136.49 (+1.22), XBIT: 27.55 (+0.18), ARIA: 9.23 (-0.04)
24.2% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Wed Apr 15, 9:51AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 4 months, Ariad Pharmaceuticals has returned 24.16% as of today's recent price of $8.84.
ARIA: 9.23 (-0.04)
Ariad Pharmaceuticals Shares Up 17.1% Since SmarTrend's Buy Recommendation (ARIA)
Comtex SmarTrend(R) - Wed Apr 08, 9:27AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 4 months, Ariad Pharmaceuticals has returned 17.13% as of today's recent price of $8.34.
ARIA: 9.23 (-0.04)
Pre-market Equity Watch on Biotech -- ARIAD Pharma, Array BioPharma, Neurocrine Biosciences, Coronado Biosciences, and Ironwood Pharma
PR Newswire - Tue Apr 07, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
NBIX: 43.23 (-0.43), IRWD: 15.07 (-0.19), CNDO: 4.09 (-0.09), ARIA: 9.23 (-0.04), ARRY: 7.25 (-0.10)
Critical Alerts For Advanced Micro Devices, Illumina, Coca-Cola, Ariad Pharmaceuticals and Ambarella Released By InvestorsObserver
PR Newswire - Mon Apr 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, ILMN, KO, ARIA and AMBA.
AMBA: 74.57 (+0.18), KO: 41.31 (+0.53), AMD: 2.28 (-0.07), ILMN: 190.04 (-9.27), ARIA: 9.23 (-0.04)
Iclusig cleared in Canada
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 8:01AM CDT
ARIA: 9.23 (-0.04)
ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada
Business Wire - Mon Apr 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that Health Canada has approved the use of Iclusig(TM) (as ponatinib hydrochloride) in Canada for the treatment of adult patients with all phases of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ ALL that is T315I mutation positive, or where there is prior TKI resistance or intolerance.
ARIA: 9.23 (-0.04)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 19.1% (ARIA)
Comtex SmarTrend(R) - Tue Mar 31, 9:58AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on December 22nd, 2014 at $7.12. In approximately 3 months, Ariad Pharmaceuticals has returned 19.10% as of today's recent price of $8.48.
ARIA: 9.23 (-0.04)
Big Selloff on Wall Street as Stocks Plummet on Fed Jitters
at The Street - Wed Mar 25, 3:27PM CDT
Wednesday was a kick-you-in-the-guts kind of day.
MU: 29.50 (+0.95), XOM: 87.46 (+0.58), IBB: 363.84 (-0.66), KRFT: 88.25 (-0.22), SOXX: 96.88 (+1.35), KFX: 11.02 (-0.01), NVDA: 22.31 (+0.25), RDS.A: 62.36 (-0.06), AMD: 2.28 (-0.07), ALXN: 188.19 (+1.41), NLNK: 53.12 (-0.07), BP: 43.24 (+0.46), ARIA: 9.23 (-0.04), CVX: 109.50 (-0.23), XLE: 81.89 (+0.54), LXK: 44.24 (+1.17)
Stocks Sell Off on Fed Jitters; Oil Rallies as Yemen Fights Intensify
at The Street - Wed Mar 25, 2:22PM CDT
Stocks are lower in a volatile trading session on Wednesday.
MU: 29.50 (+0.95), IBB: 363.84 (-0.66), KRFT: 88.25 (-0.22), SOXX: 96.88 (+1.35), KFX: 11.02 (-0.01), NVDA: 22.31 (+0.25), AMD: 2.28 (-0.07), ALXN: 188.19 (+1.41), NLNK: 53.12 (-0.07), ARIA: 9.23 (-0.04), BRK.A: 214,789.00 (+1,349.00), LXK: 44.24 (+1.17)
ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court
Business Wire - Wed Mar 25, 8:28AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig(R) (ponatinib) on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy.
ARIA: 9.23 (-0.04)
ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel
Business Wire - Tue Mar 24, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig(R) (ponatinib) in Israel for adult patients with:
ARIA: 9.23 (-0.04)
Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 4.42% Rise
Comtex SmarTrend(R) - Thu Mar 19, 4:37PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.57 to a high of $9.09. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $8.78 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 9.23 (-0.04)
ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting
Business Wire - Thu Mar 19, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2015, taking place Saturday, April 18 through Wednesday, April 22, 2015, in Philadelphia.
ARIA: 9.23 (-0.04)
